Yasunori Kaneko Net Worth

The estimated Net Worth of Yasunori Kaneko is at least $363 mil dollars as of 23 April 2021. Yasunori Kaneko owns over 4,133 units of Arcus Biosciences Inc stock worth over $121,047 and over the last 7 years he sold RCUS stock worth over $0. In addition, he makes $241,482 as Lead Independent Director at Arcus Biosciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Yasunori Kaneko RCUS stock SEC Form 4 insiders trading

Yasunori has made over 2 trades of the Arcus Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 4,133 units of RCUS stock worth $129,652 on 23 April 2021.

The largest trade he's ever made was exercising 35,000 units of Arcus Biosciences Inc stock on 4 June 2020 worth over $279,650. On average, Yasunori trades about 4,348 units every 36 days since 2017. As of 23 April 2021 he still owns at least 7,133 units of Arcus Biosciences Inc stock.

You can see the complete history of Yasunori Kaneko stock trades at the bottom of the page.

Yasunori Kaneko biography

Dr. Yasunori Kaneko M.D. serves as Lead Independent Director of the Company. Dr. Kaneko was a Managing Director at Skyline Venture Partners, L.P., a venture capital firm, from January 1999 to January 2019. Dr. Kaneko previously served as Chief Financial Officer and Vice President, Business Development at Tularik, Inc., a biopharmaceutical company, at various times from 1992 until 1999. Dr. Kaneko served as a Senior Vice President and Chief Financial Officer of Ionis Pharmaceuticals, Inc., a pharmaceutical company, which went public in May 1991 during his tenure from 1991 to 1992. Dr. Kaneko began his career at Genentech, Inc., a biotechnology company, where he served in a business development role, from 1981 to 1987 and as head of corporate finance in the investment banking division of Paribas Capital Markets LTD, from 1987 to 1991. Dr. Kaneko is a member of the Stanford Interdisciplinary Life Sciences Council and serves on the board of Provigate Inc. Dr. Kaneko served on the board of Nippon Paint Holdings Co., Ltd. from March 2018 to March 2020, and previously served on the board of LeukoSite Inc., a biopharmaceutical company, until its merger with Millennium Pharmaceuticals, Inc. in 1999. Dr. Kaneko received an undergraduate degree and a medical degree from Keio University in Tokyo, and an M.B.A. from Stanford Graduate School of Business. Kaneko is able to make valuable contributions to our Board of Directors due to his educational background in medicine, as well as his experience in the life science, pharmaceutical and related financial industries.

What is the salary of Yasunori Kaneko?

As the Lead Independent Director of Arcus Biosciences Inc, the total compensation of Yasunori Kaneko at Arcus Biosciences Inc is $241,482. There are 7 executives at Arcus Biosciences Inc getting paid more, with William Grossman having the highest compensation of $3,400,310.

How old is Yasunori Kaneko?

Yasunori Kaneko is 66, he's been the Lead Independent Director of Arcus Biosciences Inc since 2015. There are no older and 15 younger executives at Arcus Biosciences Inc.

What's Yasunori Kaneko's mailing address?

Yasunori's mailing address filed with the SEC is C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD, CA, 94545.

Insiders trading at Arcus Biosciences Inc

Over the last 7 years, insiders at Arcus Biosciences Inc have traded over $12,714,957 worth of Arcus Biosciences Inc stock and bought 22,383,260 units worth $566,530,309 . The most active insiders traders include Patrick Machado, Sciences, Inc. Gilead, eHarbor Master Investors (Ca.... On average, Arcus Biosciences Inc executives and independent directors trade stock every 32 days with the average trade being worth of $5,400,635. The most recent stock trade was executed by Alexander Azoy on 13 August 2024, trading 1,357 units of RCUS stock currently worth $20,314.

What does Arcus Biosciences Inc do?

arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be

Complete history of Yasunori Kaneko stock trades at Collegium Pharmaceutical Inc e Arcus Biosciences Inc

Arcus Biosciences Inc executives and stock owners

Arcus Biosciences Inc executives and other stock owners filed with the SEC include:

• William Grossman,
  Chief Medical Officer
• Juan Jaen,
  President, Co-Founder, Director
• Terry Rosen,
  Chairman of the Board, Chief Executive Officer, Co-Founder
• Jennifer Jarrett M.B.A.,
  COO & Director
• Jennifer Jarrett,
  Chief Operating Officer, Director
• Patrick Machado,
  Director
• Antoni Ribas,
  Director
• Yasunori Kaneko,
  Lead Independent Director
• Kathryn Falberg,
  Independent Director
• Merdad Parsey,
  Director
• David Lacey,
  Director
• Eric Hoefer,
  Chief Commercial Officer & Head of Business Development
• Jason Barker,
  Vice President - Finance
• Robert Goeltz,
  Chief Financial Officer, Principal Financial and Accounting Officer
• Yvonne Gehring,
  VP of HR & Operations
• Holli Kolkey,
  VP of Corp. Communications
• Carolyn C. Tang J.D.,
  Gen. Counsel & Corp. Sec.
• Katherine Bock,
  VP of Investor Relations & Corp. Strategy
• Dr. Jonathan Yingling Ph.D.,
  Chief Scientific Officer
• Dr. Stephen Young Ph.D.,
  Sr. VP of Technology & Quantitative Biology
• Robert C. Goeltz II,
  Principal Financial & Accounting Officer and CFO
• Dr. Juan Carlos Jaen Ph.D.,
  Co-Founder, Pres & Director
• David W Beier,
  Director
• Carolyn C. Tang,
  General Counsel
• Harbor Master Investors (Ca...,
  10% owner
• 2016 Gp, L.L.C.Gv 2016 Gp, ...,
  
• 2017 Gp, L.L.C.Gv 2017 Gp, ...,
  
• Group Ii, Lp Column Group I...,
  
• Kristen Hege,
  Director
• Steven Chan,
  See Remarks
• Rekha Hemrajani,
  See Remarks
• Sciences, Inc. Gilead,
  10% owner
• Nicole Lambert,
  Director
• Dimitry Sa Nuyten,
  Chief Medical Officer
• Alexander Azoy,
  Chief Accounting Officer